Trials / Sponsors / Forma Therapeutics, Inc.
Forma Therapeutics, Inc.
Industry · 10 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediat Sickle Cell Disease | Phase 2 | 2023-06-20 |
| Recruiting | A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disea Sickle Cell Disease | Phase 2 | 2023-01-12 |
| Terminated | A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R | Phase 2 | 2022-11-15 |
| Completed | A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Sickle Cell Disease, Thalassemia | Phase 2 | 2022-03-28 |
| Active Not Recruiting | A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Sickle Cell Disease | Phase 3 | 2021-01-29 |
| Terminated | A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity | Phase 1 / Phase 2 | 2019-05-17 |
| Completed | A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients Healthy Volunteers, Sickle Cell Disease | Phase 1 | 2018-12-11 |
| Completed | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma | Phase 1 / Phase 2 | 2018-11-01 |
| Completed | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2016-04-30 |
| Completed | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | 2015-09-01 |